|
[1]
|
Boucai, L., Seshan, V., Williams, M., Knauf, J.A., Saqcena, M., Ghossein, R.A., et al. (2021) Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score. The Journal of Clinical Endocrinology & Metabolism, 107, 1030-1039. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Sabbagh, M.F., Janovitz, T., Dias-Santagata, D., Siegmund, S., Nardi, V., Wirth, L.J., et al. (2024) FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy. Thyroid®, 34, 1137-1149. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Wang, Z., Han, Q., Hu, X., et al. (2025) Multi-Omics Clustering Analysis Carries out the Molecular-Specific Subtypes of Thyroid Carcinoma: Implicating for the Precise Treatment Strategies. Genes & Immunity, 26, 137-150. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Raue, F. and Frank-Raue, K. (2025) What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma. In: Raue, F. and Frank-Raue, K. Eds., Medullary Thyroid Carcinoma, Springer Nature, 1-8. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Shobab, L., Al-Souri, D., Mathews-Kim, L., McCoy, M., Kuenstner, W., Hubbard, G.K., et al. (2024) PD-L1 Expression Varies in Thyroid Cancer Types and Is Associated with Decreased Progression Free Survival (PFS) in Patients with Anaplastic Thyroid Cancer. Cancers, 16, Article 3632. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Matrone, A., Citro, F., Gambale, C., Prete, A., Minaldi, E., Ciampi, R., et al. (2023) BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review. Journal of Clinical Medicine, 12, Article 6970. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Armos, R., Bojtor, B., Podani, J., Illyes, I., Balla, B., Putz, Z., et al. (2024) Descriptive Analysis of Common Fusion Mutations in Papillary Thyroid Carcinoma in Hungary. International Journal of Molecular Sciences, 25, Article 10787. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Boruah, M., Gaddam, P., Agarwal, S., Mir, R.A., Gupta, R., Sharma, M.C., et al. (2023) PD-L1 Expression in Rare and Aggressive Thyroid Cancers: A Preliminary Investigation for a Role of Immunotherapy. Journal of Cancer Research and Therapeutics, 19, 312-320. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Okafor, C., Hogan, J., Raygada, M., Thomas, B.J., Akshintala, S., Glod, J.W., et al. (2021) Update on Targeted Therapy in Medullary Thyroid Cancer. Frontiers in Endocrinology, 12, Article 708949. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Prabhash, K., Saldanha, E., Patil, V., et al. (2024) RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer. JCO Precision Oncology, 8, e2300622. [Google Scholar] [CrossRef]
|
|
[11]
|
Yu, F., Zeng, G., Yang, L., Zhou, H. and Wang, Y. (2024) LAMB3: Central Role and Clinical Significance in Neoplastic and Non-Neoplastic Diseases. Biomedicine & Pharmacotherapy, 178, Article 117233. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Trocchianesi, S., Po, A., Citarella, A., Spinello, Z., Rughetti, A., Besharat, Z.M., et al. (2023) Molecular Mechanisms of the Tyrosine Kinase Inhibitor Pralsetinib Activity in in-vitro Models of Medullary Thyroid Carcinoma: Aberrant Activation of the HH-Gli Signaling Pathway in Acquired Resistance. Biomedicine & Pharmacotherapy, 164, Article 114995. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Cruz-Romero, S.D., González, S., Juez, J.Y., Becerra, D.S., Baldión, A.M., Hakim, J.A., et al. (2024) TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort. Advances in Therapy, 41, 792-805. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Chiba, T. (2024) Molecular Pathology of Thyroid Tumors: Essential Points to Comprehend Regarding the Latest WHO Classification. Biomedicines, 12, Article 712. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Hang, J., Chen, J., Kuo, P., Lai, H., Lee, T., Tai, S., et al. (2023) A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors with Emphasis on Braf-Negative Cases. Modern Pathology, 36, Article 100242. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Alexandraki, K.I., Papadimitriou, E., Spyroglou, A., Karapanagioti, A., Antonopoulou, I., Theohari, I., et al. (2024) Immunohistochemical Expression of Ephrin Receptors in Neuroendocrine Neoplasms: A Case-Series of Gastroenteropancreatic Neuroendocrine Neoplasms and a Systematic Review of the Literature. Endocrine, 87, 1323-1332. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Melone, V., Salvati, A., Palumbo, D., Giurato, G., Nassa, G., Rizzo, F., et al. (2022) Identification of Functional Pathways and Molecular Signatures in Neuroendocrine Neoplasms by Multi-Omics Analysis. Journal of Translational Medicine, 20, Article No. 306. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Alsugair, Z., Descotes, F., Lopez, J., Lasolle, H., Chazot, F.B., Lifante, J., et al. (2024) Clinically Aggressive Follicular Cell-Derived Thyroid Carcinoma: A Comprehensive Series with Histomolecular Characterization and Discovery of Novel Gene Fusions. Human Pathology, 153, Article 105674. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Rivera, J.P. and Hang, J. (2025) Next-Generation Immunohistochemistry in Thyroid Neoplasm: A Practical Review on the Applications in Diagnosis and Molecular Classification. Endocrine Pathology, 36, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Gao, X., Hong, C., Xie, Y. and Zeng, X. (2023) Immunotherapy or Targeted Therapy: What Will Be the Future Treatment for Anaplastic Thyroid Carcinoma? Frontiers in Oncology, 13, Article 1103147. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Qin, L., Chen, C., Gui, Z. and Jiang, Y. (2024) IRX5’s Influence on Macrophage Polarization and Outcome in Papillary Thyroid Cancer. Frontiers in Oncology, 14, Article 1399484. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Mortensen, A.C.L., Imgenberg-Kreuz, J., Spiegelberg, D., Botling, J. and Nestor, M. (2023) Utilizing CD44v6 and V600EBRAF-Mutation for in vitro Targeted Combination Therapy of Thyroid Carcinomas. Heliyon, 9, e22594. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Zhang, L., Feng, Q., Wang, J., Tan, Z., Li, Q. and Ge, M. (2023) Molecular Basis and Targeted Therapy in Thyroid Cancer: Progress and Opportunities. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1878, Article 188928. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Currie, G. (2024) Molecular Theranostics: Principles, Challenges and Controversies. Journal of Medical Radiation Sciences, 72, 156-164. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Hamidi, S. and Maniakas, A. (2023) Recent Advances in Anaplastic Thyroid Cancer Management. Current Opinion in Endocrinology, Diabetes & Obesity, 30, 259-264. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Voinea, I., Petrova, E., Dumitru, N., Cocoloș, A., Ioachim, D., Goldstein, A.L., et al. (2024) Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms toward Therapeutic Approaches: A Comprehensive Review. Journal of Clinical Medicine, 13, Article 7161. [Google Scholar] [CrossRef] [PubMed]
|